Brief: Innovation Pharmaceuticals Exploring Lead Defensin Mimetic Drug Candidate Brilacidin As Potential Novel Coronavirus Treatment
18/02/2020 20:46
Feb 18 (Reuters) - Innovation Pharmaceuticals Inc IPIX.PK :
* INNOVATION PHARMACEUTICALS EXPLORING LEAD DEFENSIN MIMETIC
DRUG
CANDIDATE BRILACIDIN AS POTENTIAL NOVEL CORONAVIRUS TREATMENT
Source text for Eikon: urn:newsml:reuters.com:*:nGNXbsJT6P
Further company coverage: IPIX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovation Pharmaceuticals
See all newsBrief: Innovation Pharmaceuticals Announces New Milestone At Beamed On Track To File 510(K) Submission To FDA In Q2 2024
Brief: Innovation Pharmaceuticals Provides Update On US Patent Applications Covering Use Of Brilacidin In Inflammatory Bowel Diseases, Coronaviruses And Fungal Diseases
Brief: Innovation Pharma Reports Enrollment In Phase 2 Trial Of Brilacidin For COVID-19 Tops 70%
Brief: Innovation Pharma Surpasses 50% Enrollment In Phase 2 Clinical Trial Of Brilacidin For COVID-19
Brief: Innovation Pharma Completes Interim Safety Data Review